share_log

StockNews.com Downgrades Pieris Pharmaceuticals (NASDAQ:PIRS) to Hold

StockNews.com Downgrades Pieris Pharmaceuticals (NASDAQ:PIRS) to Hold

斯托克新聞降級皮耶斯製藥公司（納斯達克：PIRS）持有
Defense World ·  2023/01/21 15:31

Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday.

皮埃爾斯製藥 (納斯達克:PIRS — 獲得評級) 在周四向客戶和投資者發布的研究報告中，股票分析師將 Stocknews.com 的評級從「買入」評級降至「持有」評級。

Pieris Pharmaceuticals Stock Performance

皮爾斯製藥股票表現

Shares of NASDAQ PIRS opened at $1.40 on Thursday. The company has a 50-day moving average of $1.07 and a 200 day moving average of $1.30. Pieris Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $3.75. The stock has a market cap of $104.17 million, a PE ratio of -2.98 and a beta of 0.95.

納斯達克 PIRS 的股票在周四的 1.40 美元開盤。該公司的移動平均線為 50 天，為 1.07 美元，200 日移動平均線為 1.30 美元。皮爾斯製藥有 12 個月低點 0.85 美元和 12 個月高點 3.75 美元。該股的市值為 10,417 萬美元，私募股票比率為 -2.98，貝塔值為 0.95。

Get
取得
Pieris Pharmaceuticals
皮耶斯制药
alerts:
警報：

Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Pieris Pharmaceuticals had a negative return on equity of 75.31% and a negative net margin of 121.78%. The firm had revenue of $5.37 million during the quarter, compared to analysts' expectations of $4.51 million. On average, sell-side analysts forecast that Pieris Pharmaceuticals will post -0.63 EPS for the current fiscal year.

皮耶斯製藥（NASDAQ：PIRS-獲取評級）上次發布了其季度收益業績於 11 月 2 日（星期三）。該生物技術公司報告了本季度每股收益（0.13 美元），超過了 0.03 美元的共識估計（0.16 美元）。皮爾斯製藥的資產回報率為 75.31%，負淨利潤率為 121.78%。該公司在本季度的收入為 537 萬美元，而分析師的預期為 451 萬美元。平均而言，賣方分析師預測皮爾斯製藥將在本會計年度發布 -0.63 每股盈利。

Institutional Investors Weigh In On Pieris Pharmaceuticals

機構投資者權衡皮爾斯製藥

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cutter & CO Brokerage Inc. grew its stake in shares of Pieris Pharmaceuticals by 1.5% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 412,229 shares of the biotechnology company's stock valued at $771,000 after buying an additional 6,000 shares during the period. Rafferty Asset Management LLC increased its stake in Pieris Pharmaceuticals by 32.3% during the second quarter. Rafferty Asset Management LLC now owns 29,622 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 7,240 shares during the last quarter. Hsbc Holdings PLC increased its stake in Pieris Pharmaceuticals by 55.6% during the first quarter. Hsbc Holdings PLC now owns 20,556 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 7,343 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Pieris Pharmaceuticals in the first quarter valued at $32,000. Finally, Blair William & Co. IL lifted its stake in shares of Pieris Pharmaceuticals by 9.1% in the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company's stock valued at $390,000 after purchasing an additional 10,760 shares during the last quarter. 47.31% of the stock is currently owned by institutional investors and hedge funds.
幾家對沖基金和其他機構投資者最近買賣了該公司的股票。Cutter＆CO 經紀公司在第二季度增長了 1.5％ 在皮耶斯製藥的股份股份的股份。在此期間額外購買 6,000 股股票後，刀具公司現在擁有該生物技術公司股票的 412,229 股，價值為 771,000 美元。拉斐蒂資產管理有限責任公司在皮埃爾斯製藥的股份增加 32.3% 在第二季度.萊佛蒂資產管理有限責任公司現在擁有 29,622 股生物技術公司的股票價值 $55,000 在上一個季度獲得了額外的 7,240 股。匯豐控股有限公司於第一季度增加了 55.6% 在皮爾斯藥業的股份。匯豐控股有限公司現在擁有該生物科技公司股票的 20,556 股，價值 63,000 美元，在上一季度額外收購 7,343 股。奥本海默 & 有限公司公司在第一季度購買了皮埃爾斯製藥的新股份，價值為 32,000 美元。最後, 布萊爾·威廉 & 有限公司.IL 在第一季度將其在皮埃爾斯製藥的股份中的股份提升了 9.1％。布萊爾·威廉 & 有限公司.IL 在上個季度額外購買 10,760 股股票後，現在擁有該生物技術公司股票的 128,745 股價值 390,000 美元。47.31％ 的股票目前由機構投資者和對沖基金擁有。

Pieris Pharmaceuticals Company Profile

皮爾斯製藥公司簡介

(Get Rating)

(取得評分)

Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Pieris 製藥公司是一家臨床階段的生物技術公司，致力於抗膽鹼藥物的發現和開發。其管道包括腫瘤免疫、呼吸系統和貧血等疾病領域。該公司由克勞斯·沙爾珀和阿恩·斯凱拉成立於 2001 年，總部位於馬薩諸塞州波士頓。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Pieris Pharmaceuticals (PIRS)
  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth
  • 獲取有關皮爾斯製藥（PIRS）的研究報告的免費副本
  • 市場節拍週的回顧 — 1/16 — 1/20
  • 老自治領是否顯示卡車正在擊中剎車？
  • 諾德斯特龍將對減價的恐懼放入零售業
  • 埃克森美孚股票：在買入點的醒目距離內
  • 高股息收益的必和必拓認為中國推動 23 年增長

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收皮埃爾斯製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Pieris 藥品和相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論